Kevin Balthaser Aclaris Therapeutics, Inc. (ACRS) insider trading activity

ACRS Quotes by TradingView

Kevin Balthaser is Chief Financial Officer of Aclaris Therapeutics, Inc.. Currently has a direct ownership of 23,983 shares of ACRS, which is worth approximately $24,702. The most recent transaction as insider was on Mar 02, 2024, when has been sold 427 shares (Common Stock) at a price of $1.24 per share, resulting in proceeds of $529. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 24K
0% 3M change
356.3% 12M change
Total Value Held $24,702

Kevin Balthaser Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 02 2024
SELL
Payment of exercise price or tax liability
$529 $1.24 p/Share
427 Reduced 1.75%
23,983 Common Stock
Mar 02 2024
BUY
Exercise of conversion of derivative security
-
1,500 Added 5.79%
24,410 Common Stock
Mar 01 2024
SELL
Payment of exercise price or tax liability
$1,227 $1.24 p/Share
990 Reduced 4.14%
22,910 Common Stock
Mar 01 2024
BUY
Exercise of conversion of derivative security
-
3,475 Added 12.84%
23,587 Common Stock
Jan 01 2024
SELL
Payment of exercise price or tax liability
$2,662 $1.05 p/Share
2,536 Reduced 11.04%
20,425 Common Stock
Jan 01 2024
BUY
Exercise of conversion of derivative security
-
7,500 Added 24.62%
22,961 Common Stock
Sep 06 2023
BUY
Open market or private purchase
$74,971 $7.9 p/Share
9,490 Added 38.03%
15,461 Common Stock
Sep 01 2023
SELL
Payment of exercise price or tax liability
$2,251 $7.9 p/Share
285 Reduced 4.56%
5,971 Common Stock
Sep 01 2023
BUY
Exercise of conversion of derivative security
-
1,000 Added 13.78%
6,256 Common Stock
Mar 03 2023
SELL
Open market or private sale
$11,291 $12.63 p/Share
894 Reduced 14.54%
5,256 Common Stock
Mar 02 2023
SELL
Open market or private sale
$12,290 $12.29 p/Share
1,000 Reduced 17.7%
4,650 Common Stock
Mar 02 2023
BUY
Exercise of conversion of derivative security
-
1,500 Added 19.61%
6,150 Common Stock
Mar 01 2023
BUY
Exercise of conversion of derivative security
-
4,950 Added 46.7%
5,650 Common Stock
KB

Kevin Balthaser

Chief Financial Officer
Wayne, PA

Track Institutional and Insider Activities on ACRS

Follow Aclaris Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ACRS shares.

Notify only if

Insider Trading

Get notified when an Aclaris Therapeutics, Inc. insider buys or sells ACRS shares.

Notify only if

News

Receive news related to Aclaris Therapeutics, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on ACRS